Polaryx Therapeutics, Inc. cotiza a 2.01 USD y tiene una capitalización bursátil de $95M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination the…
| Periodo | 2026-05 | 2026-03 |
|---|---|---|
| Real | $-0.05 | $-0.16 |
| Estimado | $-0.02 | $-0.02 |
| Sorpresa | -150.0% | -700.0% |
| Métrica | PLYX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -196.8% | -40.4% | -156.4% |
| ROA | -173.8% | -32.0% | -141.8% |
| Current Ratio | 8.55 | 2.84 | +5.71 |
| Debt / Equity | — | 0.28 | — |